Back to top

Analyst Blog

BioScrip, Inc. (BIOS - Analyst Report) recently declared its third-quarter 2013 results. Adjusting for certain one-time expenses BioScrip reported earnings were 1 cents in the quarter, declining from the year-ago earnings figure of 2 cents. The results were in line with the Zacks Consensus Estimate of 1 cent.

Following the announcement on Nov 6, stock price of BioScrip declined 15.8% to $6.05 per share on Nov 11.

On a reported basis, BioScrip’s net loss was $34.1 million or 53 cents per share considerably exceeded the net loss of $11.5 million or 20 cents per share incurred in the year-ago quarter.

Revenues in Detail

Total revenues rose 22.6% year over year to $208.8 million, beating the Zacks Consensus Estimate of $205 million. The company operates through three main segments, viz. Infusion Services (83% of total revenues), Home Health Services (8.6%) and PBM Services (7.6%).

Segments in Detail

The company reported revenues of $174.8 million in Infusion Services, recording impressive growth of 38.8% year over year. Organic growth and acquisitions were the major revenue drivers in this segment.

Revenues in the Home Health Services segment increased 4.46% to $18.1 million. The rise came on the back of volume improvement from private duty nursing activity, partially offset by a reduction in reimbursement rates.

Revenues in the PBM Services segment were $16 million, down 41% from the prior-year quarter. The decline was due to lower sales volume of discount cards and termination of a contract with a PBM client.

Operational Update

While the cost of product revenues shot up 34.9% to $115.5 million, the cost of service revenues declined 7.9% to $24.6 million in the quarter.

Gross profit during the quarter increased 18.4% year over year to $68.6 million on account of greater volume of business generated from Infusion Services. However, gross margin contracted 110 basis points (bps) to 32.9% owing to business mix. The downfall resulted from the Infusion Services segment growing more rapidly than the higher-margin PBM Services segment.

Selling, general and administrative (SG&A) expenses increased 24% to $57.9 million. The hike in expenditure resulted in a drag of 135 bps in adjusted operating margin, which settled at 3.2% for the reported quarter.

Financial Update

The company ended the quarter as on Sep 30, 2013, with no cash balance as all its cash had been utilized. The long-term debt was $415.5 million as on Sep30, 2013 as compared to $226.4 million on Dec30, 2104.


For 2013, BioScrip continues to expect revenues of $830–$850 million.

Our Take

Despite the core business of the company generating positive growth, it delivered a satisfactory quarter, as revenues could not surpass the estimates.

BioScrip is focusing on the implementation of a company-wide profit improvement plan to deliver robust operating performance in the future. Such an initiative will help it to generate greater savings through acquisition-related synergies, improved operating efficiencies and reductions in SG&A expenses. We are also optimistic about the recent acquisitions being accretive for the company’s business in the long run.

Currently, the stock carries a Zacks Rank #3 (Hold). Other stocks that are worth a look include Rite Aid Corporation (RAD - Analyst Report) sporting a Zacks Rank #1 (Strong Buy), and CVS Caremark Corporation (CVS - Analyst Report) and GNC Holdings Inc. (GNC - Snapshot Report), each carrying a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.81 +7.32%
WEATHERFORD… WFT 23.80 +3.88%
BANCO DO BR… BDORY 14.49 +3.87%
EQT MIDSTRE… EQM 97.46 +2.67%
GREEN PLAIN… GPRE 44.97 +2.65%